Basket 09 — Regulatory Strategy
US FDA
505(b)(2) Ideas
Potential repurposing, new dosage form, new route, new combination and lifecycle extension opportunities under the US FDA 505(b)(2) pathway.
Status
Ideas basket — concept and opportunity stage. Specific product names to be finalised after internal review.
Concept Areas
The US FDA 505(b)(2) pathway is not a shortcut — it is a legitimate regulatory framework that allows new drug applications to rely, in part, on published literature or existing FDA drug approval findings for at least some portion of the evidence needed for approval. For a manufacturer with GMP-certified API capability and niche therapeutic focus, 505(b)(2) represents an entry mechanism into the US regulated market that does not require a full de novo clinical programme for each molecule.
Pathway Mechanics
Six regulatory opportunity types
New Dosage Form
MediumConverting an existing approved drug into a new physical form — tablet to patch, solution to microsphere, immediate-release to modified-release. The 505(b)(2) pathway allows reliance on the safety and efficacy data of the reference listed drug (RLD), requiring only bridging studies for the new form.
Oral → transdermal, IM injectable → subcutaneous depot, immediate-release → extended-release capsule
New Route of Administration
Medium–HighRepurposing an approved molecule via a different delivery route that achieves a meaningfully different pharmacokinetic or clinical outcome. The regulatory argument centres on the new clinical benefit while retaining reliance on the known safety database of the parent compound.
Oral → intravesical, systemic → topical, IV → inhalation
Modified-Release Concept
MediumEngineering the release kinetics of an approved molecule to reduce dosing frequency, smooth plasma concentration curves, reduce peak-related adverse effects, or achieve site-specific release. A well-characterised pharmacokinetic-pharmacodynamic model underpins the regulatory submission.
Once-daily formulation of a twice-daily molecule, gastric-retention systems, colon-targeted delivery
Fixed-Dose Combination
Medium–HighCombining two or more individually approved molecules into a single dosage form where the combination demonstrates additive or synergistic clinical value, simplifies treatment, or improves adherence meaningfully over co-administration. The 505(b)(2) route allows reliance on each component's existing approval while adding combination-specific bridging data.
Alpha-blocker + 5-ARI combination tablets, OCP combination optimisation, anti-emetic combinations
New Strength or Packaging
Low–MediumRegulatory opportunities exist where an approved molecule lacks a clinically useful dose strength or patient-appropriate packaging format — paediatric doses, geriatric unit-dose packaging, or precision dose strengths for specific subpopulations.
Paediatric dosing strengths, geriatric blister unit doses, precision microdose formulations
Repurposing / New Use Concept
High — indication-specific trials requiredExtending an approved molecule into a new indication where existing safety data supports the regulatory argument and the clinical evidence base is emerging. The 505(b)(2) pathway is ideally suited: the full safety database is inherited; only efficacy for the new indication requires demonstration.
IC/BPS indications for existing urological molecules, neuropathy adjunct use for metabolic drugs